After more than 20 years of research on arenaviruses, an Institut Pasteur team led by Sylvain Baize has developed an original vaccine platform known as MOPEVAC, which will strengthen the Institut Pasteur's pandemic preparedness initiatives. A Phase Ia clinical trial led by a research team at the Institut Pasteur is set to begin for the platform's first vaccine candidate, which targets Lassa fever, a hemorrhagic fever responsible for thousands of deaths worldwide each year. In the long term, the MOPEVAC platform will enable scientists to respond to the emergence of new viruses with effective candidate vaccines aimed at pathogens with high mortality rates. The MOPEVAC clinical trials are funded by the France 2030 program as part of the "Emerging infectious diseases and CBRN threats" strategy. They are led by the French Health Innovation Agency and operated on behalf of the French government by Bpifrance, which also supported the preclinical trials.

In this study, researchers estimated the amount of greenhouse gas emissions generated by patients traveling to and from medical appointments in the U.S. The team used a national transportation survey that includes distance travelled, vehicle and fuel type. The team found that health care travel generates about 35.7 megatons of carbon emissions each year—roughly the same as the emissions from the electricity used by seven million homes in a year.

Scheduling practices significantly impact job satisfaction for nurses at all levels, with flexibility, transparency, equity, and autonomy key factors for scheduling success, according to a new study led by researchers at NYU Rory Meyers College of Nursing. 

The study, published in the Western Journal of Nursing Research, also describes nurses’ pragmatic solutions for improving scheduling processes.

Register now for a complimentary media pass for the ATS 2025 International Conference in San Francisco. We will have breaking news from the leading international conference for pulmonary, critical care and sleep medicine.